What is PBM's current stock price?

PBM (Psyence Biomedical Ltd.) is currently trading at $4.10 with a market cap of $78.0K.

What sector is Psyence Biomedical Ltd. in?

Psyence Biomedical Ltd. (PBM) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

PBM Psyence Biomedical Ltd.

Healthcare

$4.10+0.99%ClosedMarket Cap: $77,978

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.35

P/S

0.00

EV/EBITDA

-5.91

DCF Value

$7.67

FCF Yield

-4801.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-47.6%

ROA

13.8%

ROIC

-54.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$0.00	$-753.3K	$—
FY null	$0.00	$1.0M	$—
Q2 null	$0.00	$141.5K	$—
FY null	$0.00	$-51.2M	$—

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.79

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

Peers